The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
Presenting at the 2022 AAN Annual Meeting, researchers assessed the safety and efficacy of monthly erenumab among adult patients with chronic migraine with Asian ancestry.
Researchers sought to establish whether frequent use of a combined biofeedback-virtual reality device is associated with improvements in chronic migraine, especially in patients refractory to pharmacotherapy.
